PT-141 (BREMELANOTIDE) NEURO ACTIVATION PEPTIDE

PT-141 (Bremelanotide) is an advanced synthetic heptapeptide that acts as a potent agonist of melanocortin receptors, particularly MC4R in the central nervous system.

Designed exclusively for professional researchers, PT-141 provides a high-quality, highly purified research tool that supports in-depth exploration of neural pathways related to desire and arousal.

RESEARCH HISTORY

The story of PT-141 began in the 1980s at the University of Arizona with the development of Melanotan II (MT-II) – a peptide originally researched for its skin-tanning properties. During clinical trials, scientists unexpectedly discovered a powerful side effect: significantly increased sexual desire and improved erectile function in volunteers.

Palatin Technologies refined the structure of MT-II by removing certain functional groups, resulting in the creation of PT-141 (Bremelanotide) in the early 2000s. It was initially tested as a nasal spray before being reformulated into a subcutaneous injection to optimize efficacy and safety.

The year 2019 marked a major milestone when the FDA approved Bremelanotide under the brand name Vyleesi® for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD), based on two large Phase 3 trials known as the RECONNECT trials.

To date (2024–2026), Palatin Technologies continues to advance research with Phase 2 trials investigating PT-141 in combination with PDE5 inhibitors (for erectile dysfunction in men who do not respond well to standard treatments) and with tirzepatide (for weight management and appetite control). These new developments are expanding the potential of melanocortin peptides across multiple research fields.

MECHANISM OF ACTION IN THE BODY

PT-141 operates through a unique Neuro Activation mechanism originating from the central nervous system, distinctly different from compounds that act peripherally (such as PDE5 inhibitors that primarily promote vasodilation).

Once in the body, PT-141 functions as a non-selective agonist of melanocortin receptors (MC1R, MC3R, MC4R, MC5R), with MC4R in the hypothalamus — particularly the medial preoptic area (mPOA) serving as the primary target.

Specific Mechanism:

  • Activating presynaptic MC4R on neurons → increases the release of dopamine (a key neurotransmitter involved in pleasure, motivation, and desire).
  • Enhances dopaminergic signaling in brain regions associated with sexual behavior, arousal, and satisfaction.
  • Does not rely on sex hormones or direct blood flow enhancement; instead, it generates desire and arousal from the brain downward, delivering a more natural response.

Thanks to this central mechanism, PT-141 is highly valued by researchers for its ability to explore deep neural pathways, extending beyond sexual function to areas such as motivation, appetite regulation, and energy balance.

POTENTIAL BENEFITS ACCORDING TO RESEARCH

PT-141 attracts strong interest from researchers due to specific data from clinical trials:

  • Improvement in Sexual Desire in Women with HSDD: In two Phase 3 RECONNECT trials (involving over 1,267 women), PT-141 at 1.75 mg increased the mean FSFI-desire score by 0.35 (p<0.001) compared to placebo. The response rate reached approximately 58% (versus 35–36% in the placebo group). It also significantly reduced distress related to low desire (FSDS-DAO item 13 decreased by –0.33, p<0.001). Benefits were well maintained in the 52-week open-label extension study.
  • Increase in Satisfying Sexual Events: Some analyses showed a substantial increase in the proportion of sexual encounters rated as “satisfying” (more than double compared to placebo in certain post-hoc analyses).
  • Support for Male Sexual Function: Phase 2 studies demonstrated clear improvements in erectile function (measured by RigiScan) and desire, particularly in men who responded poorly to PDE5 inhibitors alone. A recent small study on 21 men using off-label PT-141 reported 91% improvement in overall sexual function, with 100% improvement in those experiencing low desire or sexual anxiety. When combined with PDE5 inhibitors, erection duration and quality increased significantly (strong synergistic effect).
  • Potential in Weight Management and Appetite Control: In the Phase 2 BMT-801 trial (2025), combining Bremelanotide with tirzepatide resulted in an additional 4.4% weight loss compared to placebo after 8 weeks (statistically significant). The combination group also showed markedly increased feelings of fullness and satiety, supporting research into appetite control via the MC4R pathway.
  • Broader Neurological and Behavioral Benefits: A powerful tool for investigating the role of dopamine and the melanocortin system in motivation, arousal, emotional connection, and pleasure-related behaviors. Researchers are actively evaluating its potential in models of desire disorders, performance anxiety, and certain aspects of brain-related obesity.

With its brain-origin Neuro Activation mechanism, PT-141 is becoming an attractive choice for laboratories seeking to lead in the field of melanocortin peptides and research on sexual function and behavior.

USAGE GUIDELINES IN RESEARCH

  • In published clinical research protocols, PT-141 is typically administered via subcutaneous injection into the abdomen or thigh.
  • Dosage according to research: The standard commonly used dose is 1.75 mg per administration. Some Phase 2 studies have used doses ranging from 0.75 mg to 2 mg depending on trial design.
  • Timing: Administer at least 45 minutes before the activity under study (typically 45–60 minutes for optimal effect).
  • Frequency: Used on demand only. Do not exceed 1 dose within 24 hours or a maximum of 8 doses per month.

Effects generally begin within 30–60 minutes and may last from several hours up to 24–72 hours, depending on the individual and dosage. In research settings, the product is used as a ready-to-inject solution or reconstituted according to approved experimental protocols.

Note: All dosages and administration methods above apply strictly within the framework of research approved by an IRB or relevant authority. They are not to be applied for any other purpose.

USAGE RECOMMENDATIONS

Groups who should not use:

  • Individuals with uncontrolled hypertension or serious cardiovascular disease
  • Pregnant or breastfeeding women, or those planning to become pregnant
  • Individuals under 18 years of age
  • Those with a history of allergy to melanocortin peptides or Bremelanotide
  • Individuals with severe liver or kidney disease (requires high caution)
  • Those taking certain medications (e.g., nitrates)

DISCLAIMER

  • PT-141 is a Research Chemical – For Research Use Only (RUO).
  • This product is not a drug and is not intended for diagnosis, treatment, or personal use. Customers are fully responsible for complying with all applicable laws and regulations.

CONCLUSION

With its unique Neuro Activation mechanism from the central nervous system, PT-141 is more than just an ordinary research peptide — it is a powerful tool that enables researchers to explore the melanocortin pathways, desire, arousal, and behavior in greater depth.

From solid clinical data to broad application potential in sexual function and weight management research, PT-141 is becoming the preferred choice for laboratories and high-level peptide specialists.

For product details, please contact:

JN Beauty Solutions®

Beauty From Science

 

#PT141 #Bremelanotide #NeuroActivationPeptide #MelanocortinPeptide #ResearchPeptide #PeptideResearch #JNBeautySolutions #BeautyFromScience